{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:59:12Z","timestamp":1790492352130,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.vaccine.2010.03.023","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T08:22:46Z","timestamp":1269678166000},"page":"3827-3840","source":"Crossref","is-referenced-by-count":91,"title":["Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity"],"prefix":"10.1016","volume":"28","author":[{"given":"Thomas P.","family":"Monath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin G.","family":"Julander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Guertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Makowiecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Crowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin C.","family":"Bowick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merribeth","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.03.023_bib1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2007.10.009","article-title":"Treatment of yellow fever","volume":"78","author":"Monath","year":"2008","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2010.03.023_bib2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jama.276.14.1157","article-title":"Yellow fever: a decade of reemergence","volume":"276","author":"Robertson","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.03.023_bib3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"Effect of prolonged cultivation in vitro upon pathogenicity of yellow fever virus","volume":"65","author":"Theiler","year":"1937","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2010.03.023_bib4","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The use of yellow fever virus modified by in vitro cultivation for human immunization","volume":"65","author":"Theiler","year":"1937","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2010.03.023_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","article-title":"Yellow fever vaccine \u2013 how does it work and why do rare cases of serious adverse events take place?","volume":"21","author":"Barrett","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib6","unstructured":"Centers for Disease Control and Prevention, Atlanta GA. Biologics Surveillance Summary; 2007."},{"key":"10.1016\/j.vaccine.2010.03.023_bib7","series-title":"Vaccines","first-page":"959","article-title":"Yellow Fever","author":"Monath","year":"2008"},{"key":"10.1016\/j.vaccine.2010.03.023_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX\u2122 and YF-VAX\u00ae) in a Phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2010.03.023_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Multisystemic illness in elderly recipients of yellow fever vaccine report of four cases","volume":"358","author":"Martin","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.03.023_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.03.023_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","article-title":"Hepatitis and death following vaccination with 17D-204 yellow fever vaccine","volume":"358","author":"Chan","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2010.03.023_bib12","unstructured":"Monath TP. Short report: suspected yellow fever vaccine associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg; in press."},{"key":"10.1016\/j.vaccine.2010.03.023_bib13","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1086\/340104","article-title":"Prevention of yellow fever in persons travelling to the tropics","volume":"34","author":"Monath","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2010.03.023_bib14","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.trstmh.2007.06.013","article-title":"Acute viscerotropic disease following vaccination against yellow fever","volume":"101","author":"Hayes","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2010.03.023_bib15","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.03.023_bib16","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.03.023_bib17","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1001\/jama.292.14.1696","article-title":"Vaccine policy changes and epidemiology of poliomyelitis in the United States","volume":"292","author":"Alexander","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.03.023_bib18","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJM196911272812201","article-title":"Complications of smallpox vaccination, 1968: national surveillance in the United States","volume":"281","author":"Lane","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2010.03.023_bib19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies","volume":"183","author":"Tesh","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.03.023_bib20","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1099\/0022-1317-78-6-1353","article-title":"Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes","volume":"78","author":"Ryman","year":"1997","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/viro.1999.9695","article-title":"Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax\u2122-JE) as a live, attenuated vaccine candidate against Japanese encephalitis","volume":"257","author":"Guirakhoo","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.03.023_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2006.08.008","article-title":"Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model","volume":"73","author":"Julander","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2010.03.023_bib23","first-page":"1052","article-title":"Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests","volume":"16","author":"Johnson","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2010.03.023_bib24","first-page":"493","article-title":"Simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am J Hyg"},{"issue":"15","key":"10.1016\/j.vaccine.2010.03.023_bib25","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1128\/JVI.75.15.6999-7008.2001","article-title":"Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa","volume":"75","author":"Mutebi","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib26","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/bmj.1.3518.976","article-title":"A yellow fever vaccine","volume":"1","author":"Hindle","year":"1928","journal-title":"Brit Med J"},{"key":"10.1016\/j.vaccine.2010.03.023_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4049\/jimmunol.30.3.221","article-title":"Study of inactivated yellow fever virus as immunizing agent","volume":"30","author":"Gordon","year":"1936","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jviromet.2008.03.002","article-title":"Pressure-inactivated yellow fever 17DD virus: implications for vaccine development","volume":"150","author":"Gaspar","year":"2008","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2010.03.023_bib29","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.vaccine.2008.12.062","article-title":"Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study","volume":"27","author":"Schuller","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.03.023_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2310\/7060.2005.12205","article-title":"Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers","volume":"12","author":"Zent","year":"2005","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2010.03.023_bib31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0091-6749(99)70245-9","article-title":"Anaphylaxis from yellow fever vaccine","volume":"103","author":"Kelso","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib32","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1016\/j.vaccine.2007.07.011","article-title":"A sensitive cell-based assay for the detection of residual infectious West Nile virus","volume":"25","author":"Koldijk","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.03.023_bib33","series-title":"The cutter incident","author":"Offitt","year":"2005"},{"key":"10.1016\/j.vaccine.2010.03.023_bib34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jim.2008.05.009","article-title":"An improved method for development of toxoid vaccines and antitoxins","volume":"337","author":"Jones","year":"2008","journal-title":"J Immunol Methods"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2010.03.023_bib35","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1086\/520605","article-title":"Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent","volume":"196","author":"Warfield","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.03.023_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/biol.1995.0034","article-title":"Inactivation of DNA by \u03b2-propiolactone","volume":"23","author":"Perrin","year":"1995","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2010.03.023_bib37","first-page":"123","article-title":"Antigenicity of beta-propiolactone inactivated virus vaccines","volume":"75","author":"LoGrippo","year":"1955","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.vaccine.2010.03.023_bib38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00277160","article-title":"Immunogenicity of a viral model vaccine after different inactivation procedures","volume":"183","author":"Bachmann","year":"1994","journal-title":"Med Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib39","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1128\/JVI.67.7.3917-3922.1993","article-title":"Formalin inactivation of vesicular stomatitis virus impairs T-cell but not T-help-independent B-cell responses","volume":"67","author":"Bachmann","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib40","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1086\/590187","article-title":"Case of yellow fever vaccine\u2014associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes","volume":"198","author":"Pulendran","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.03.023_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nature Rev Immunol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib42","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1016\/j.vaccine.2007.08.061","article-title":"Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease","volume":"25","author":"Belsher","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.03.023_bib43","first-page":"131","article-title":"Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection","volume":"85","author":"Kengsakul","year":"2002","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.vaccine.2010.03.023_bib44","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(04)17017-7","article-title":"Eidex for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination","volume":"364","author":"Barwick","year":"2004","journal-title":"Lancet"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2010.03.023_bib45","doi-asserted-by":"crossref","first-page":"e1000614","DOI":"10.1371\/journal.ppat.1000614","article-title":"A mouse model for studying viscerotropic disease caused by yellow fever virus infection","volume":"5","author":"Meier","year":"2009","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2010.03.023_bib46","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2010.03.023_bib47","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1086\/320200","article-title":"Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology","volume":"183","author":"Xiao","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2010.03.023_bib48","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib49","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2010.03.023_bib50","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1016\/j.vaccine.2007.06.035","article-title":"Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections","volume":"25","author":"Scherer","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.03.023_bib51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1084\/jem.20051720","article-title":"Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity","volume":"203","author":"Querec","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2010.03.023_bib52","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines","volume":"28","author":"Miller","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2010.03.023_bib53","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/ni.1645","article-title":"Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway","volume":"9","author":"Cao","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2010.03.023_bib55","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant vaccine against West Nile virus","volume":"103","author":"Monath","year":"2006","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"10.1016\/j.vaccine.2010.03.023_bib56","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/hv.2.2.2555","volume":"2","author":"Guirakhoo","year":"2006","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2010.03.023_bib57","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10003592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10003592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T08:36:37Z","timestamp":1685522197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10003592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":57,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S0264410X10003592"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.03.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}